As of May 25
| -0.03 / -1.88%|
The 5 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 1.00. The median estimate represents a +27.39% increase from the last price of 1.57.
The current consensus among 5 polled investment analysts is to Hold stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.